Senate Finance Committee report revealed, three companies Novo Nordisk, Sanofi and Eli Lilly control 99 percent of the marketplace and have worked in lockstep to limit competition and increase prices: Over The Past Decade, The Three Largest Manufacturers Of Insulin Novo Nordisk, Sanofi And Eli Lilly Aggressively Raised The List Price Of Their Insulin Products Absent Significant Advances In The Efficacy Of The Drugs. Sanofis long-acting insulin pens, Lantus SoloStar, increased from $303 in 2014 to $404 in 2019
This peptide mimics the bodys natural growth hormone (GH) pulses , so strategically timing your doses can enhance its effects on muscle growth, recovery, fat burning , and sleep quality
Saxenda (Liraglutide) is the only GLP-1 medication approved in Singapore for weight loss
Nature 468(7325):824828 Upile T et al (2011) Vascular mimicry in cultured head and neck tumour cell lines
Hinson 2010)
That's the mechanistic rationale for the combination, not generic 'synergy.' The difference between effective and ineffective tesamorelin stacking comes down to receptor biology, not dosage escalation